Edotecarin

Drug Profile

Edotecarin

Alternative Names: ED 749; J-107088; PF-804950; PHA-782615

Latest Information Update: 21 Aug 2009

Price : $50

At a glance

  • Originator Banyu; Merck & Co
  • Class Antineoplastics; Carbazoles; Indoles
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Colorectal cancer; Glioblastoma

Most Recent Events

  • 17 Jan 2006 Discontinued - Phase-III for Glioblastoma in USA (IV-injection)
  • 17 Jan 2006 Data presented at the 13th European Cancer Conference (ECCO-2005) have been added to the Cancer therapeutic trials section
  • 05 Apr 2005 Pfizer has terminated its license for edotecarin worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top